ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: 2272 • 2016 ACR/ARHP Annual Meeting

    The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide

    Nicola Dalbeth1, Jordyn de Kwant1, Gregory Gamble2, Amanda Phipps-Green3, Anne Horne2, Robert Doughty1, Lisa K. Stamp4 and Tony R. Merriman5, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose: Diuretic use is strongly associated with development of hyperuricaemia and gout.  Genetic variation in the renal uric acid transporters SLC2A9 (encoding GLUT9) and SLC22A11…
  • Abstract Number: 3075 • 2016 ACR/ARHP Annual Meeting

    Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population

    Tony R. Merriman1, James Boocock2, Nicola Dalbeth3, Lisa K. Stamp4, Eli A. Stahl5, Hyon K. Choi6, Elizabeth Matisoo-Smith7 and Anna Gosling8, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, 6Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 7Anatomy, University of Otago, Dunedin, New Zealand, 8Biochemistry, University of Otago, Dunedin, New Zealand

    Background/Purpose: Mitochondria play a central role in induction of an NLRP3 inflammatory response essential for gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5…
  • Abstract Number: 218 • 2016 ACR/ARHP Annual Meeting

    Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture

    Stephanie Fabre1, Jean-Marie Launay1, Jean-François Gautier1, Adam Platt2, Jeffrey N. Miner3, Glen Hughes2, Pascal Richette4 and Thomas Bardin1, 1Hôpital Lariboisière, Paris, France, 2AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 3Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 4Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose:  A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or…
  • Abstract Number: 2278 • 2016 ACR/ARHP Annual Meeting

    Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank

    Murray Cadzow1, Tony R. Merriman2 and Nicola Dalbeth3, 1University of Otago, Dunedin, New Zealand, 2Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand

    Background/Purpose : Accurate case-definition is important for epidemiological studies of gout. However, in multipurpose cohort studies frequently used for genome wide association studies, limited information…
  • Abstract Number: 3139 • 2016 ACR/ARHP Annual Meeting

    Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout

    Pieusha Malhotra1, Nikky Keer2 and Robert Yood3, 1Internal Medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, 2Internal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, 3Department of rheumatology and musculoskeletal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA

    Background/Purpose: Despite available effective treatment options and published guidelines for gout management, many patients suffer from recurrent gout attacks. Increases in gout prevalence and continued…
  • Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting

    Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects

    Michael Gillen1, Zangong Shen2 and Jeffrey N. Miner3, 1AstraZeneca, Gaithersburg, MD, 2Ardea Biosciences, San Diego, CA, 3Discovery Biology, Ardea Biosciences, Inc., San Diego, CA

    Background/Purpose:  This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…
  • Abstract Number: 219 • 2016 ACR/ARHP Annual Meeting

    Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol

    Nicola Dalbeth1, Savvas Nicolaou2, Scott Baumgartner3, Jia Hu3, Maple Fung3 and Hyon K. Choi4, 1University of Auckland, Auckland, New Zealand, 2Radiology, University of British Columbia, Vancouver, BC, Canada, 3Ardea Biosciences, Inc., San Diego, CA, 4Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…
  • Abstract Number: 2280 • 2016 ACR/ARHP Annual Meeting

    Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout

    Ashika Chhana1, Mei-Lin Tay2, Bregina Pool3, Karen E. Callon2, David Musson2, Dorit Naot1, Gregory Gamble3, Jillian Cornish3 and Nicola Dalbeth2, 1Medicine, University of Auckland, Auckland, New Zealand, 2University of Auckland, Auckland, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose:   Bone erosion in gout is strongly associated with tophi; lesions comprising of inflammatory cells surrounding collections of monosodium urate (MSU) crystals.  Osteocytes are…
  • Abstract Number: 3199 • 2016 ACR/ARHP Annual Meeting

    Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study

    Patapong Towiwat1, Anthony Doyle1, Gregory Gamble2, Paul Tan1, Opetaia Aati2, Anne Horne2, Lisa K. Stamp3 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, New Zealand

    Background/Purpose:  Imaging and pathology studies have shown that bone erosion is closely associated with monosodium urate (MSU) crystal deposition in tophaceous gout.  It is currently…
  • Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting

    Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects

    James VanderLugt1, Michael Gillen2, Xiaojuan Yang3 and Jesse Hall3, 1Jasper Clinical Research & Development, Kalamazoo, MI, 2AstraZeneca, Gaithersburg, MD, 3Ardea Biosciences, Inc., San Diego, CA

    Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
  • Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting

    Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout

    Siddharth K. Das1, Harikrishnan Velayudhan2, Danveer Bhadu3, Urmila Dhakad4 and Ragini Srivastava5, 1Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, 2Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India, 3Rheumatology, Senior Resident III, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, 4Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, 5Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India

    Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…
  • Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting

    Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)

    Anil Singh1, Kayla O’Sullivan2, Mukesh Chourasia3, Sadiq Umar4, Mahamudul Haque2, Bhanupriya Madarampalli2 and Salahuddin Ahmed2, 1Washington State University, College of Pharmacy, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 3Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, 4Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA

    Background/Purpose:   Methods:   Results:   Conclusion:  
  • Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting

    Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study

    William B Smith1, Jesse Hall2, Jolene Berg3, Michal Kazimir4, Amy Yamamoto2, Caroline Lee2, Susan Walker2 and Thomas C. Marbury5, 1Volunteer Research Group, Knoxville, TN, 2Ardea Biosciences, Inc., San Diego, CA, 3DaVita Clinical Research, Minneapolis, MN, 4DaVita Clinical Research, Lakewood, CO, 5Orlando Clinical Research Center, Orlando, FL

    Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…
  • Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting

    Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York

    Lara El Khoury1, Mohamad Yasmin1,2, Nabil Zeineddine1, Joseph Saabiye1, Saleha Riaz1, Sami Arnaout1, Talal El Imad1, Suzanne El-Sayegh3 and Rita Obeid4, 1Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, 2Infectious Diseases, Case Western Reserve University, Cleveland, OH, 3Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, 4Psychology, The Graduate Center, CUNY, New York, NY

    Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…
  • Abstract Number: 2284 • 2016 ACR/ARHP Annual Meeting

    Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization

    Rashid Ahmed1, Nicole Yang2, Changqi Sun3 and Anthony M. Reginato3, 1Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, 3Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI

    Background/Purpose:  Gouty arthritis is a common inflammatory joint disease that arises in response to the deposition of monosodium urate (MSU) crystals in soft joints, periarticular…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology